Tykerb® (Lapatinib): Comparative data have shown that lapatinib based regimens are less effective than trastuzumab based regimens for metastatic breast cancer (mBC) in certain settings

User Rating: 0 / 5

Star InactiveStar InactiveStar InactiveStar InactiveStar Inactive
 

Date: 04 April 2014

Description: A Direct Healthcare Professional Communication (DHPC) has been issuedto inform healthcare professionals of comparative data showing that lapatinib-based regimens are less effective than trastuzumab-based regimens in certain settings.Tykerb®, a kinase inhibitor, is indicated in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumours overexpress HER2 and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. Prescribers are reminded that Tykerb® should not be prescribed in combination with capecitabine unless patients have received prior therapy that must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting.Please refer to the DHPC for more details.

National Pharmaceutical Regulatory Agency (NPRA)
Lot 36, Jalan Universiti, 46200 Petaling Jaya, Selangor, Malaysia.
  • Email: npra@npra.gov.my
  • Phone: +603-7883 5400
  • Fax: +603-7956 2924, +603-7956 7075

DISCLAIMER

The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Mobile Web :

© Copyright 2018 . All Rights Reserved National Pharmaceutical Regulatory Agency NPRA